Oncologists often say “I need a PhD in molecular pharmacology to understand the latest developments and new treatments in this field.”  Well, short of having your own PhD, the next best thing is to borrow the expertise of one.  To that end, I’m very pleased to welcome to our faculty Dr. Kelly Quesnelle, who recently completed her PhD dissertation on mechanisms of resistance to EGFR-based therapies at the University of Pittsburgh.  She is a lab-based scientist who received her BS in Cell & Molecular Biology from the University of Michigan, then spent time working in the labs at Pfizer and GlaxoSmithKline, followed by research at the University of Pennsylvania Medical School in Philadelphia.   She then moved to the University of Pittsburgh Medical School  to pursue her PhD in molecular pharmacology.   

She has won multiple awards for her research, and she also prioritizes scientific writing, as a member of the American Medical Writers Association.  

Continue reading →